Santosh K Ghosh

US Patent:

20100022025, Jan 28, 2010

Filed:

Feb 23, 2009

Appl. No.:

12/390890

Inventors:

AARON WEINBERG - Shaker Heights OH, US
Santosh K. Ghosh - Mayfield Heights OH, US

International Classification:

G01N 33/566

US Classification:

436501

Abstract:

A method of detecting β-defensin in a bodily sample from a subject includes reducing the electrostatic interaction between β-defensin and negatively charged moieties in the bodily sample prior to detecting the β-defensin with an antibody or epitope binding fragment thereof.

US Patent:

20210088521, Mar 25, 2021

Filed:

Oct 16, 2020

Appl. No.:

17/072076

Inventors:

- Cleveland OH, US
Santosh Ghosh - Mayfield Heights OH, US
Umut A. Gurkan - Cleveland OH, US

International Classification:

G01N 33/574
G01N 33/543
C12Q 1/68
C12Q 1/6886
B01L 3/00

Abstract:

A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.

US Patent:

20180364242, Dec 20, 2018

Filed:

Dec 15, 2016

Appl. No.:

16/062175

Inventors:

- Cleveland OH, US
Santosh Ghosh - Mayfield Heights OH, US
Umut A. Gurkan - Cleveland OH, US

International Classification:

G01N 33/574
B01L 3/00
G01N 33/543

Abstract:

A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.